How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,360 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Qtern (saxagliptin / dapagliflozin propanediol monohydrate) - Diabetes Mellitus, Type 2

Qtern (saxagliptin / dapagliflozin propanediol monohydrate) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 26 May 2016 EMA/428168/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) 2 diabetes mellitus TAMC Total Aerobic Microbial Count TB Total bilirubin TC Total cholesterol TG Triglycerides Qtern Assessment report Page 6/91 TGA Thermo-Gravimetric Analysis TYMC Total Combined Yeast/Mould Count TZD UDU Thiazolidinedione Unit Dose Uniformity UGT UHPLC Uridine diphosphate glucuronosyl transferase Ultra High Performance Liquid Chromatography UKPDS United Kingdom Prospective Diabetes Study Group ULN USP Upper limit of normal United States Pharmacopoeia UTI Urinary tract

2016 European Medicines Agency - EPARs

62. The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus

The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect (...) of Shear- Force at the Skin in Patients With Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02348294 Recruitment Status : Unknown Verified January 2015 by Maastricht University Medical Center. Recruitment status was: Not yet recruiting First Posted : January 28, 2015 Last Update

2015 Clinical Trials

63. Treatment and recommendations for homeless people with Diabetes Mellitus

adaptation. Hopefully, these simple adaptations of established diabetes guidelines can help improve treatment adherence and health outcomes for patients experiencing homelessness. TREATMENT AND RECOMMENDATIONS FOR PATIENTS WHO ARE HOMELESS WITH DIABETES MELLITUS 2 DIAGNOSIS AND EVALUATION History Current Symptoms ? Ask patients if they have had any symptoms of hypoglycemia or hyperglycemia. Ask questions regarding complications of diabetes (i.e., vision changes, paresthesias, skin changes/ulcers, chest (...) patients are doing as well as the condition and fit of footwear. ? Obtain a sexual history including contraception and reproductive history. TREATMENT AND RECOMMENDATIONS FOR PATIENTS WHO ARE HOMELESS WITH DIABETES MELLITUS 3 Social History ? Assess where patients are living; e.g., shelter, on the street, doubled up. (“Doubled up” is a term that refers to a situation where individuals are unable to maintain their housing situation and are forced to stay with a series of friends and/or extended family

2013 National Health Care for the Homeless Council

64. Skin Conditions in Diabetes Mellitus

Skin Conditions in Diabetes Mellitus Skin Conditions in Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Skin (...) Conditions in Diabetes Mellitus Skin Conditions in Diabetes Mellitus Aka: Skin Conditions in Diabetes Mellitus , Diabetic Skin Disorders II. Associated Conditions: Diabetes Mellitus related See Xanthoma diabeticorum Xanthomas suggest Bullosis Diabeticorum (rare) e on extremities (especially feet) Usually heel without scarring Diabetic Ulcer Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Skin Conditions in Diabetes Mellitus." Click

2015 FP Notebook

65. Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)

Details Study Description Go to Brief Summary: The study aims to investigate effects of inhibiting glucocorticoid activation on skin function and wound healing in patients with type 2 diabetes. Half of patients will be given a drug to inhibit glucocorticoid activation and the other half will be given a placebo. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: AZD4017 Drug: Placebo Phase 2 Detailed Description: Glucocorticoids are known to impair skin function and wound (...) information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Ana Tiganescu, PhD, University of Leeds: skin wound healing 11 beta-hydroxysteroid dehydrogenase type 1 Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Niacinamide Vitamin B Complex Vitamins Micronutrients Nutrients Growth Substances Physiological

2017 Clinical Trials

66. Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.

is to determine which variables can be used to predict plantar pressure and skin temperature and which factors are associated with the development of foot ulcers in patients with established diagnosis of diabetic foot. The associations between skin temperature and plantar pressure will also be addressed. Condition or disease Diabetic Foot Diabetes Study Design Go to Layout table for study information Study Type : Observational [Patient Registry] Estimated Enrollment : 100 participants Observational Model (...) Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients. Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

67. CPG for Diabetes Mellitus Type 1

pen 144 8.6.1.1. Adults 144 8.6.1.2. Children and adolescents 145 8.6.2. Comparison of pre-? lled pens 146 8.7. Insulin administration techniques 147 8.7.1. Administration site: injection site 147 8.7.2. Rotation of injection points 148 8.7.3. Injection technique (injection angle and skin fold) 149 8.7.4. Reusing needles 151 8.7.5. Injection through the clothes 151 8.7.6. Needle Size 152 8.8. Indications for the treatment with metformin added to insulin in adolescents with diabetes mellitus type 1 (...) it alone. People with diabetes mellitus type 1 and their families should be encouraged to monitor blood glucose levels before and after exercise to learn about the glycaemic response to different exercise conditions, and make the necessary adjustments before, during or after exercising. People with diabetes mellitus type 1 and their families should be informed of the risk of late hypoglycaemia in situations of intense and/or prolonged exercise, to take the necessary precautions. People with diabetes

2012 GuiaSalud

68. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

inhibitors, SGLT-2 inhibitors, and SGLT-1/SGLT-2 inhibitors may be considered experimental drugs being tested for adjunctive therapy in T1D adult patients. As such, their place in therapy in the management of T1D still needs to be defined. Background Diabetes mellitus is a metabolic disorder that results from defects in insulin secretion, insulin action, or both. 1 There are two major categories of diabetes. Type 1 diabetes (T1D) is characterized by severe impairment or an absolute deficiency of insulin (...) .) Note: Table adapted from Table 7 in Endocrine and Metabolic Disorders: Diabetes Mellitus Chapter of Therapeutic Choices. © Canadian Pharmacists Association, 2016. All rights reserved. Source: . Accessed: November 30, 2016. Other information sources include the Government of Canada Notice of Compliance Database 29 and the Government of Canada Drug and Health Product Register. 34 Patient Group Insulin is a life-saving drug for T1D patients. 10 However, some T1D patients have difficulty obtaining

2018 CADTH - Issues in Emerging Health Technologies

69. Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/insulin aspart Drug: biphasic insulin aspart Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 263 (...) Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2016 Clinical Trials

70. Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: semaglutide Drug: sitagliptin Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 500 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Efficacy (...) Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2016 Clinical Trials

71. A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Description Go to Brief Summary: The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM) Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: LGD-6972-5 mg Drug: LGD-6972-10 mg Drug: LGD-6972-15 mg Other: Placebo Phase 2 Detailed Description: This will be a 12-week, randomized, double-blind, placebo-controlled, 4 (...) and 40 kg/m2, inclusive, and must weigh more than 45 kg Exclusion Criteria: History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia or hypoglycemia unawareness Women of childbearing potential, lactating, or has a positive pregnancy test History or presence of alcoholism or drug abuse within 2 years prior to screening Unwilling to comply with study restrictions, including restrictions on strenuous exercise Presence of any of the following conditions: renal

2016 Clinical Trials

72. Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

: Completed First Posted : August 11, 2016 Last Update Posted : August 1, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug (...) Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

73. Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

: July 24, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: semaglutide Drug: empagliflozin Phase 3 Study Design Go to Layout table (...) Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2016 Clinical Trials

74. Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

: Terminated (manufacturing-related issues) First Posted : August 11, 2016 Last Update Posted : March 29, 2018 Sponsor: Janssen Research & Development, LLC Information provided by (Responsible Party): Janssen Research & Development, LLC Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase (...) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2016 Clinical Trials

75. Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Identifier: NCT02963922 Recruitment Status : Completed First Posted : November 15, 2016 Last Update Posted : October 26, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin. Condition or disease (...) Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2016 Clinical Trials

76. An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

will be randomized 1:1 to receive either albiglutide (starting dose of 30 milligrams [mg] once weekly for 4 weeks, followed by 50 mg once weekly for 4 weeks) or exenatide (starting dose of 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 4 weeks). The total duration of a subject's participation in the study will be approximately 15 weeks. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Exenatide Drug: Albiglutide Phase 4 Study Design Go to Layout table for study (...) An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2016 Clinical Trials

77. A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record (...) managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus The safety and scientific

2016 Clinical Trials

78. A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre- ix/Combination I

-diabetic drugs Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: Insulin degludec/liraglutide Drug: Insulin degludec Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 210 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: This Trial is Conducted in Asia. The Aim of This Trial (...) A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre- ix/Combination I A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix

2016 Clinical Trials

79. Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

ratio to either Albiglutide active liquid auto-injector (LAI) plus Placebo lyophilized DCC pen injector (lyophilized DCC PI); or, Albiglutide lyophilized DCC PI plus Placebo LAI. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Lyophilized albiglutide DCC pen injector Drug: Lyophilized albiglutide DCC pen injector matching placebo Drug: Albiglutide liquid auto-injector Drug: Albiglutide liquid auto-injector matching placebo Phase 3 Study Design Go to Layout table (...) Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2016 Clinical Trials

80. Betafoam Diabetes Mellitus Foot Study

the efficacy and safety of Medifoam® and Betafoam®, which is a new dressing that contains povidone-iodine, in patients with diabetes foot ulcer. 70 patients (35 each arm) are targeted to be enrolled in this study. Treatment follow periods are 8weeks. Condition or disease Intervention/treatment Phase Diabetes Mellitus Foot Ulcer Device: Medifoam® Device: Betafoam® Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 71 (...) Betafoam Diabetes Mellitus Foot Study Betafoam Diabetes Mellitus Foot Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Betafoam Diabetes Mellitus Foot Study The safety and scientific validity

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>